Are inhibitors of histone deacetylase 8 (HDAC8) effective in hematological cancers especially acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)?

被引：16
|
作者：
Amin, Sk Abdul [1 ,2 ]
Khatun, Samima [3 ]
Gayen, Shovanlal [3 ]
Das, Sanjib [1 ]
Jha, Tarun [1 ]
机构：
[1] Jadavpur Univ, Dept Pharmaceut Technol, Div Med & Pharmaceut Chem, Nat Sci Lab, Kolkata 700032, India
[2] JIS Univ, Dept Pharmaceut Technol, 81 Nilgunj Rd, Kolkata, West Bengal, India
[3] Jadavpur Univ, Dept Pharmaceut Technol, Lab Drug Design & Discovery, Kolkata 700032, India
来源：
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2023年 / 258卷
关键词：
Cancer; Hematological malignancy; HDAC; HDAC8; inhibitor; Enzyme selectivity; HYDROXAMIC ACID-DERIVATIVES; BIOLOGICAL EVALUATION; DRUG DISCOVERY; CELL-GROWTH; DNA-BINDING; P53; DESIGN; ACETYLATION; POTENT; THERAPY;
D O I：
10.1016/j.ejmech.2023.115594
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Histone deacetylase 8 (HDAC8) aberrantly deacetylates histone and non-histone proteins. These include structural maintenance of chromosome 3 (SMC3) cohesin protein, retinoic acid induced 1 (RAI1), p53, etc and thus, regulating diverse processes such as leukemic stem cell (LSC) transformation and maintenance. HDAC8, one of the crucial HDACs, affects the gene silencing process in solid and hematological cancer progressions especially on acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). A specific HDAC8 inhibitor PCI-34051 showed promising results against both T-cell lymphoma and AML. Here, we summarize the role of HDAC8 in hematological malignancies, especially in AML and ALL. This article also introduces the structure/function of HDAC8 and a special attention has been paid to address the HDAC8 enzyme selectivity issue in hematological cancer especially against AML and ALL.
引用
收藏
页数：26
相关论文
共 50 条
  • [21] Histone deacetylase inhibition improves differentiation of dendritic cells from leukemic blasts of patients with TEL/AML1-positive acute lymphoblastic leukemia
    Schmidt, Kerstin
    Seeger, Karl
    Scheibenbogen, Carmen
    Bender, Roderich
    Abdulla, Majd
    Suessmilch, Sina
    Salama, Abdulgabar
    Moldenhauer, Anja
    JOURNAL OF LEUKOCYTE BIOLOGY, 2009, 85 (03) : 563 - 573
  • [22] An immediate transcriptional signature associated with response to the histone deacetylase inhibitor Givinostat in T acute lymphoblastic leukemia xenografts
    Pinazza, M.
    Borga, C.
    Agnusdei, V.
    Minuzzo, S.
    Fossati, G.
    Paganin, M.
    Michielotto, B.
    De Paoli, A.
    Basso, G.
    Amadori, A.
    te Kronnie, G.
    Indraccolo, S.
    CELL DEATH & DISEASE, 2016, 7 : e2047 - e2047
  • [23] K-Means Clustering on 3rd order Polynomial based Normalization of Acute Myeloid Leukemia (AML) and Acute Lymphocyte Leukemia (ALL)
    Mehdi, Ahmed M.
    Sehgal, Mohammad Shoaib
    Zayegh, Aladin
    Begg, Rezaul
    Manan, Abdul
    2009 THIRD INTERNATIONAL CONFERENCE ON ELECTRICAL ENGINEERING, 2009, : 36 - +
  • [24] Homoharringtonine synergy with oridonin in treatment of t(8;21) acute myeloid leukemia
    Zhang, Weina
    Lu, Ying
    Zhen, Tao
    Chen, Xinjie
    Zhang, Ming
    Liu, Ping
    Weng, Xiangqin
    Chen, Bing
    Wang, Yueying
    FRONTIERS OF MEDICINE, 2019, 13 (03) : 388 - 397
  • [25] ZMYND8-regulated IRF8 transcription axis is an acute myeloid leukemia dependency
    Cao, Zhendong
    Budinich, Krista A.
    Huang, Hua
    Ren, Diqiu
    Lu, Bin
    Zhang, Zhen
    Chen, Qingzhou
    Zhou, Yeqiao
    Huang, Yu-Han
    Alikarami, Fatemeh
    Kingsley, Molly C.
    Lenard, Alexandra K.
    Wakabayashi, Aoi
    Khandros, Eugene
    Bailis, Will
    Qi, Jun
    Carroll, Martin P.
    Blobel, Gerd A.
    Faryabi, Robert B.
    Bernt, Kathrin M.
    Berger, Shelley L.
    Shi, Junwei
    MOLECULAR CELL, 2021, 81 (17) : 3604 - +
  • [26] Discovery of WDR5-MLL1 and HDAC Dual-Target Inhibitors for the Treatment of Acute Myeloid Leukemia
    Long, Guanlu
    Wang, Xianghan
    Chen, Xin
    Ma, Sai
    Sun, Liangkui
    Jiang, Zhengyu
    You, Qidong
    Guo, Xiaoke
    JOURNAL OF MEDICINAL CHEMISTRY, 2025, 68 (02) : 1260 - 1279
  • [27] Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis
    Diab, Adi
    Zickl, Lynette
    Abdel-Wahab, Omar
    Jhanwar, Suresh
    Gulam, Manjit A.
    Panageas, Katherine S.
    Patel, Jay P.
    Jurcic, Joseph
    Maslak, Peter
    Paietta, Elisabeth
    Mangan, James K.
    Carroll, Martin
    Fernandez, Hugo F.
    Teruya-Feldstein, Julie
    Luger, Selina M.
    Douer, Dan
    Litzow, Mark R.
    Lazarus, Hillard M.
    Rowe, Jacob M.
    Levine, Ross L.
    Tallman, Martin S.
    LEUKEMIA RESEARCH, 2013, 37 (01) : 32 - 36
  • [28] A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor
    Li, Yin
    Chen, Kai
    Zhou, Yong
    Xiao, Yiren
    Deng, Manman
    Jiang, Zhiwu
    Ye, Wei
    Wang, Xiangmeng
    Wei, Xinru
    Li, Jie
    Liang, Jiabao
    Zheng, Zhongxin
    Yao, Yao
    Wang, Weiguang
    Li, Peng
    Xu, Bing
    CURRENT CANCER DRUG TARGETS, 2015, 15 (06) : 493 - 503
  • [29] Successful Outcome of a Case of Acute Myeloid Leukemia with t(8;21)/AML-ETO Following Langerhans Cell Histiocytosis
    Meng, Guangqiang
    Wang, Jingshi
    Huang, Jiancheng
    Wang, Yini
    Wei, Na
    Wang, Zhao
    TURKISH JOURNAL OF HEMATOLOGY, 2019, 36 (04) : 294 - 296
  • [30] CXCL8 is associated with the recurrence of patients with acute myeloid leukemia and cell proliferation in leukemia cell lines
    Li, Yuanye
    Cheng, Jingying
    Li, Ying
    Jiang, Yajing
    Ma, Jiao
    Li, Qinghua
    Pang, Tianxiang
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2018, 499 (03) : 524 - 530
12345